What is different at commercial scale

Commercial manufacturing changes the failure mode: a lost clinical batch delays a study, while a lost commercial batch creates a stock-out for patients and a reportable supply problem. Three dimensions change at once.

Supply reliability. Clinical campaigns are episodic. Commercial supply is a forecast with safety stock, a contracted campaign cadence and a batch success rate tracked as a key performance indicator. Every rejected batch must be replaced inside the forecast window, so resins, media and single-use assemblies need second sources.

Regulatory exposure. The site is named in Module 3.2.S.2.1 of the dossier. The US FDA inspects it before licensure, Japan's PMDA inspects in connection with a product approval, and EU authorities require an inspection by an EEA competent authority, or reliance under a mutual recognition agreement, before issuing a GMP certificate. After approval, every process change falls under ICH Q5E comparability principles. The CDMO's quality system becomes part of the sponsor's license.

Cost of goods. Titer, downstream yield, resin lifetime, consumable cost and facility utilization set the cost per gram. A ten-point change in utilization or yield moves margin more than any price negotiation, so commercial manufacturing contracts need transparent cost drivers, not just a price per batch.

Capacity models: stainless steel versus single-use 2,000 L trains

For most antibodies at commercial titers of several grams per liter, 2,000 L single-use trains give the shortest path to launch; stainless steel pays back only at very high, stable volumes. The table lists the criteria that matter in a commercial manufacturing evaluation.

Annual output is arithmetic: working volume multiplied by titer, overall yield and batches per year. A 2,000 L bioreactor at 3 g/L and 70% downstream yield gives roughly 4 kg per batch, so a train running 20 batches a year supplies about 80 kg. Ask the CDMO to run that calculation for your molecule before comparing price per gram.

Reading a regulatory track record: TFDA PIC/S, PMDA and FDA approvals

An approval means that a specific site passed a specific inspection for a specific product scope, so read the certificate rather than the press release. Each regulator issues a different kind of evidence about a commercial manufacturing partner.

• Taiwan FDA under PIC/S. Taiwan's inspectorate is a PIC/S participating authority and inspects against the PIC/S GMP Guide, which is harmonized with EU GMP Parts I and II. A current PIC/S GMP certificate signals EU-equivalent expectations, and inspection reports can be shared between member authorities.
• Japan PMDA. PMDA conducts GMP compliance inspections of foreign manufacturers in connection with product applications; ask what scope the inspection covered.
• US FDA. The FDA issues no standalone GMP certificate. A site is "FDA-approved" when a Biologics License Application naming it is approved after a pre-license inspection. Ask for the inspection classification and how observations were closed.
• EU. GMP certificates are issued by national competent authorities after inspection. For a non-EU site, the sponsor's qualified person relies on that certificate or a mutual recognition arrangement.

Then ask which products the inspections covered, when the last one took place, and whether more than one authority has inspected the same quality system.

Technology transfer and PPQ into the commercial site

The transfer package and the PPQ campaign are where launch timelines are won or lost, so ask the CDMO to show both as documents, not slides. ICH Q10 names technology transfer as a lifecycle stage, and the FDA's 2011 process validation guidance places process performance qualification at Stage 2 of three.

A complete transfer package into commercial manufacturing contains the process description with set points and ranges, the critical process parameters and quality attributes with justification, the bill of materials with grades and suppliers, transferable analytical methods, and the scale-down data behind the ranges. The receiving site performs a gap assessment, runs at least one engineering batch at full scale, and documents any process change for comparability under ICH Q5E before PPQ starts.

For the PPQ campaign itself, the decision criteria are concrete:

1. Analytical methods validated and transferred to site QC before the first PPQ batch.
2. The number of PPQ batches justified by process understanding and risk, not defaulted to three.
3. Enhanced sampling beyond routine release, with pre-defined criteria for intra- and inter-batch variability.
4. A PPQ report format that drops into Module 3.2.S.2.5 of the dossier.

Supply chain and business continuity

Business continuity is designed in at site selection and cannot be added by contract later. A commercial manufacturing agreement should name the mitigation for each risk that could stop supply for a full campaign cycle.

Second site with overlapping scale. A CDMO with two cGMP sites under one quality system can move a process between them with a comparability exercise instead of a new vendor qualification. Check that the second site has bioreactors that can carry your volume.

Cell bank protection. Master and working cell banks are the only irreplaceable materials in the supply chain. They belong under continuous environmental monitoring with alarms, with a backup set at a separate location.

Drug substance inventory. Frozen bulk held at a validated storage condition is the cheapest insurance against a lost campaign. Sponsors commonly hold several months of drug substance at launch.

Materials and logistics. Validated shipping for frozen bulk and a natural-hazard plan complete the picture.

Evaluation scorecard

Score a commercial manufacturing candidate on evidence you can hold in your hand, and weight the criteria that are hardest to fix after signing.

A candidate that scores well on price but cannot produce certificates and PPQ documentation is a clinical supplier, not a commercial manufacturing partner.